74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Guardant Health Inc
Closed
SectorHealthcare
41.98 -3.49
Overview
Share price change
24h
Min
40.06
Max
43.29
Income | -3.3M -111M |
|---|---|
Sales | 10M 202M |
EPS | -0.62 |
Profit margin | -55.004 |
Employees | 1,999 |
EBITDA | -2.7M -99M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +28.77% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | -726M 5.3B |
|---|---|
Previous open | 45.47 |
Previous close | 41.98 |
News Sentiment
By Acuity
50%
50%
166 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Guardant Health Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Guardant Health Inc Forecast
Price Target
By TipRanks
28.77% upside
12 Months Forecast
Average 56 USD 28.77%
High 65 USD
Low 42 USD
Based on 20 Wall Street analysts offering 12 month price targets forGuardant Health Inc - Dist in the last 3 months.
Sentiment
By Acuity
166 / 386 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
